New Parkinson's Disease Findings from Korea Institute of Science and Technology Described (Optogenetic Inactivation of the Subthalamic Nucleus Improves Forelimb Akinesia in a Rat Model of Parkinson Disease)
By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Fresh data on Parkinson's disease are presented in a new report. According to news reporting originating from Seoul, South Korea, by NewsRx correspondents, research stated, "The inhibition of neuronal activity by electrical deep brain stimulation is one of the mechanisms explaining the therapeutic effects in patients with Parkinson disease (PD) but cannot specifically activate or inactivate different types of neurons. Recently, a new technology based on optogenetics has been developed to modulate the activity of specific neurons."
Our news editors obtained a quote from the research from the Korea Institute of Science and Technology, "However, the therapeutic effects of optical inactivation in the subthalamic nucleus (STN) have not been fully investigated. To perform various behavioral tests to evaluate changes in motor functions in a PD rat model after optogene expression and, unlike previous studies, to assess the therapeutic effects of direct optogenetic inactivation in the STN. 6-Hydroxydopamine-induced hemiparkinsonian rats received injections of hSynapsin1-NpHR-YFP adeno-associated virus or an equivalent volume of phosphate-buffered saline. Three weeks after injection of adeno-associated virus or phosphate-buffered saline, the optic fiber was implanted into the ipsilateral STN. A stepping test, a cylinder test, and an apomorphine-induced rotation test were performed in 3 sequential steps: during light-off state, during light stimulation, and again during light-off state. Stepping tests revealed that optical inhibition of the STN significantly improved 6-hydroxydopamine-induced forelimb akinesia. PD motor signs, as assessed by cylinder and apomorphine tests, were not affected by optical inhibition. Immunofluorescence revealed that halorhodopsin was highly expressed and colocalized with vesicular glutamate transporter 2 in the STN. Optogenetic inhibition in the STN may be effective in improving contralateral forelimb akinesia but not in changing forelimb preference or reducing dopaminergic receptor supersensitivity."
According to the news editors, the research concluded: "These findings are useful as a basis for future studies on optogenetics in PD."
For more information on this research see: Optogenetic Inactivation of the Subthalamic Nucleus Improves Forelimb Akinesia in a Rat Model of Parkinson Disease. Neurosurgery, 2014;74(5):533-541. Neurosurgery can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Neurosurgery - journals.lww.com/neurosurgery/pages/default.aspx)
The news editors report that additional information may be obtained by contacting H.H. Yoon, Korea Inst Sci & Technol, Center Bion, Seoul, South Korea. Additional authors for this research include J.H. Park, Y.H. Kim, J. Min, E. Hwang, C.J. Lee, J.K.F. Suh, O. Hwang and S.R. Jeon (see also Parkinson's Disease).
Keywords for this news article include: Asia, Biotechnology, Seoul, South Korea, Gene Therapy, Bioengineering, Brain Diseases, Movement Disorders, Parkinson's Disease, Basal Ganglia Diseases, Parkinsonian Disorders, Neurodegenerative Diseases, Central Nervous System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC